Traws Pharma, Inc. (TRAW)
NASDAQ: TRAW · Real-Time Price · USD
1.690
+0.010 (0.60%)
May 13, 2026, 11:24 AM EDT - Market open
Traws Pharma Employees
As of December 31, 2025, Traws Pharma had 7 total employees, including 6 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$398,571
Profits / Employee
$980,714
Market Cap
17.17M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 7 | 0 | - | 4 | 3 |
| Dec 31, 2024 | 7 | -11 | -61.11% | 6 | 1 |
| Dec 31, 2023 | 18 | 1 | 5.88% | 17 | 1 |
| Dec 31, 2022 | 17 | 2 | 13.33% | 16 | 1 |
| Dec 31, 2021 | 15 | 3 | 25.00% | 14 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Vistagen Therapeutics | 59 |
| Quince Therapeutics | 38 |
| Curis | 24 |
| Outlook Therapeutics | 17 |
| Lantern Pharma | 16 |
| VYNE Therapeutics | 10 |
| Exicure | 8 |
| AEON Biopharma | 8 |
TRAW News
- 4 days ago - Traws Pharma files to sell 35.9M shares of common stock for holders - TheFly
- 4 days ago - There are no hantavirus treatments. The deadly cruise-ship outbreak is a ‘wake-up call' to develop some. - Market Watch
- 5 days ago - Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections - GlobeNewsWire
- 27 days ago - Traws Pharma Earnings Call Transcript: Q4 2025 - Transcripts
- 27 days ago - Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights - GlobeNewsWire
- 2 months ago - Traws Pharma completes clinical analysis of Phase 2 study of ratutrelvir - TheFly
- 2 months ago - Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza - GlobeNewsWire
- 3 months ago - Traws Pharma initiated with a Buy at Ladenburg - TheFly